Xeris Biopharma Holdings, Inc. XERS
10.35 USD +0.18 (+1.77%)
At closeNov 4, 2026, 4:20 AM EST
10.51 +0.16 +1.55%
Pre-market · Nov 4, 4:20 AM ET
10.17 Day range 10.56
5.25 52-week range 11.42
- YTD
- +31.85%
- 1 year
- +4.55%
News
defenseworld.net Xeris Biopharma (NASDAQ:XERS) vs. Cocrystal Pharma (NASDAQ:COCP) Head-To-Head Contrast Cocrystal Pharma (NASDAQ: COCP - Get Free Report) and Xeris Biopharma (NASDAQ: XERS - Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare…
businesswire.com Xeris Biopharma Welcomes Menassie M. Taddese to Board of Directors CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a leading endocrine and rare disease biopharmaceutical company committed to helping people realize better lives through the…
gurufocus.com Xeris Biopharma Holdings Inc (XERS) Stock Down 6.1% but Still Overvalued -- GF Score: 66/100 On October 23, 2026, Xeris Biopharma Holdings Inc (XERS) shares fell 6.1% to a current price of $10.20, within a 52-week range of $5.25 to $11.42. This price mo
gurufocus.com Xeris Biopharma to Report Third Quarter 2026 Financial Results and Business Highlights on November 5, 2026 Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a leading, endocrine and rare disease biopharmaceutical company committed to helping people realize better lives
businesswire.com Xeris Biopharma to Report Third Quarter 2026 Financial Results and Business Highlights on November 5, 2026 CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a leading, endocrine and rare disease biopharmaceutical company committed to helping people realize better lives through the…
defenseworld.net Organon & Co. (NYSE:OGN) & Xeris Biopharma (NASDAQ:XERS) Critical Comparison Organon and Co. (NYSE: OGN - Get Free Report) and Xeris Biopharma (NASDAQ: XERS - Get Free Report) are both healthcare companies, but which is the better business? We will compare the two businesses…
businesswire.com Xeris Biopharma Reinforces Leadership in Endocrinology With Data Disclosures Spanning Commercial Portfolio and Pipeline at Multiple Scientific Meetings CHICAGO--(BUSINESS WIRE)--XERIS BIOPHARMA REINFORCES LEADERSHIP IN ENDOCRINOLOGY WITH DATA DISCLOSURES SPANNING COMMERCIAL PORTFOLIO & PIPELINE AT MULTIPLE SCIENTIFIC MEETINGS.
benzinga.com Xeris Biopharma Files Patent Infringement Lawsuits Related To Its KEYEVIS Product In U.S. District Court In New Jersey On October 13, 2026, Xeris Biopharma Holdings, Inc. (the "Company"), through its wholly owned subsidiary, Xeris Pharmaceuticals, Inc., filed patent infringement lawsuits in the United States District…
fool.com Better Healthcare ETF: VanEck's Biotech-Focused BBH vs. State Street's XPH Targeting Pharma BBH concentrates on 25 large-cap biotech leaders, while XPH diversifies across 62 pharmaceutical holdings. Both charge 0.35% annually, but their five-year returns diverged significantly.
benzinga.com Barclays Maintains Overweight on Xeris Biopharma Holdings, Raises Price Target to $14 Barclays analyst Glen Santangelo maintains Xeris Biopharma Holdings (NASDAQ:XERS) with a Overweight and raises the price target from $12 to $14.
benzinga.com Full Transcript: Xeris Biopharma Holdings Q2 2026 Earnings Call Xeris Biopharma Holdings (NASDAQ:XERS) released second-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below. This content is powered by Benzinga APIs.…
defenseworld.net Analyzing Xeris Biopharma (NASDAQ:XERS) and Corcept Therapeutics (NASDAQ:CORT) Xeris Biopharma (NASDAQ: XERS - Get Free Report) and Corcept Therapeutics (NASDAQ: CORT - Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two…
businesswire.com Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative…
defenseworld.net Xeris Biopharma (NASDAQ:XERS) Shares Climb 5.2% – Here’s What Happened Xeris Biopharma Holdings, Inc. (NASDAQ: XERS - Get Free Report) traded up 5.2% during mid-day trading on Monday. The company traded as high as $9.38 and last traded at $9.5750. Approximately 460,484…
reuters.com Lundbeck expresses interest in buying Xeris, Bloomberg News reports Danish drugmaker H Lundbeck A/S has expressed interest in acquiring Chicago-based Xeris Biopharma , Bloomberg News reported on Tuesday, citing people familiar with the matter.
defenseworld.net Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Given Average Recommendation of “Hold” by Analysts Shares of Xeris Biopharma Holdings, Inc. (NASDAQ: XERS - Get Free Report) have received an average rating of "Hold" from the seven ratings firms that are presently covering the firm, MarketBeat…
seekingalpha.com Xeris Biopharma Holdings, Inc. (XERS) Discusses XP-8121 Program Overview, Phase 3 Study Details and Commercial Strategy Transcript Xeris Biopharma Holdings, Inc. (XERS) Discusses XP-8121 Program Overview, Phase 3 Study Details and Commercial Strategy Transcript
gurufocus.com Xeris Hosts Webinar Detailing Its Comprehensive Development Program for XP-8121, an Investigational, Once-Weekly Subcutaneous Levothyroxine for Hypothyroidism Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing i
businesswire.com Xeris Hosts Webinar Detailing Its Comprehensive Development Program for XP-8121, an Investigational, Once-Weekly Subcutaneous Levothyroxine for Hypothyroidism CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative…
defenseworld.net Connor Clark & Lunn Investment Management Ltd. Takes $1.01 Million Position in Xeris Biopharma Holdings, Inc. $XERS Connor Clark and Lunn Investment Management Ltd. bought a new position in shares of Xeris Biopharma Holdings, Inc. (NASDAQ: XERS) during the second quarter, according to its most recent Form 13F…
defenseworld.net Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Given Average Recommendation of “Hold” by Brokerages Xeris Biopharma Holdings, Inc. (NASDAQ: XERS - Get Free Report) has received an average recommendation of "Hold" from the six brokerages that are covering the firm, MarketBeat Ratings reports. One…
businesswire.com Xeris Announces Details for XP-8121 Program Overview Webinar CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative…
seekingalpha.com Xeris Biopharma: A Commercial Stage Pharma That May Be A Slow-Burn Buy Opportunity Xeris Biopharma Holdings, Inc. achieved record 2024 revenues of $203M, up 24%, with robust growth across all three commercial products. 2025 revenue guidance of $255M–$275M implies 30% growth for…